NCT00236639 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity Posted on November 22, 2017 by tsuperadmin -
NCT00266617 – The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy Posted on November 10, 2017 by tsuperadmin -
NCT00269997 – The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy Posted on November 10, 2017 by tsuperadmin -
NCT02025907 – A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy Posted on October 26, 2017 by tsuperadmin -
NCT01340664 – A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Posted on October 26, 2017 by tsuperadmin -
NCT01381900 – A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea Posted on October 26, 2017 by tsuperadmin -
NCT01809327 – A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise Posted on October 26, 2017 by tsuperadmin -
A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type Posted on October 13, 2017 by tsuperadmin -
NCT00082602 – Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer’s Disease Posted on September 20, 2017 by tsuperadmin -
Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial Posted on September 7, 2017 by tsuperadmin -
The YODA Project